Strategic Priorities 2002-2004
Drive development programs for expanded indications of ONTAK, Targretin capsules
Ramp up second wave of R&D for priority early-stage products; advance at least 3 into clinical development
Expand marketed specialty products portfolio through in-licensing or acquisitions
Improve capital structure by reducing non-operating expense